Generation of an HIV-1-resistant immune system with CD34+ hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5719-5729

  Walker, Jon E ^a   Chen, Rachel X ^b   McGee, Jeannine ^a   Nacey, Catherine ^a   Pollard, Richard B ^a   Abedi, Mehrdad ^a   Bauer, Gerhard ^a   Nolta, Jan A ^a   Anderson, Joseph S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; INTERLEUKIN 2 RECEPTOR GAMMA; ISOPROTEIN; LENTIVIRUS VECTOR; RAG1 PROTEIN; SHORT HAIRPIN RNA; TRIPARTITE MOTIF PROTEIN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; BONE MARROW; CD34 SELECTION; CELL SURFACE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC TRANSDUCTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN; THYMUS; TREATMENT RESPONSE; VIRAL GENE THERAPY; VIRUS STRAIN;

ANIMALS; ANTIGENS, CD34; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; LENTIVIRUS; MICE; TISSUE THERAPY; TRANSDUCTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84861309293     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06300-11     Document Type: Article

References (29)

1. An DS, et al. 2007. Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc. Natl. Acad. Sci. U. S. A. 104:13110-13115.
2. Anderson J, et al. 2007. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy- in SCID-hu mouse-derived T cells. Mol. Ther. 15:1182-1188.
3. Anderson J, Akkina R. 2007. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Gene Ther. 14:1287-1297.
4. Anderson J, Akkina R. 2008. Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34+(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue. Hum. Gene Ther. 19:217-228.
5. Anderson JS, Javien J, Nolta JA, Bauer G. 2009. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5alpha protein, a CCR5 shRNA, and a TAR decoy. Mol. Ther. 17: 2103-2114.
6. Berges BK, Rowan MR. 2011. The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 8:65.
7. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. J. Infect. Dis. 203:1204-1214.
8. Denton PW, Garcia JV. 2009. Novel humanized murine models for HIV research. Curr. HIV/AIDS Rep. 6:13-19.
9. DiGiusto DL, et al. 2010. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2:36ra43.
10. Ding SF, Lombardi R, Nazari R, Joshi S. 2002. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and transdominant negative mutant Gag and Env proteins. Front. Biosci. 7:15-28.
11. Feeney ER, Mallon PW. 2010. Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation. Curr. Pharm. Des. 16:3339-3351.
12. Huang Y, et al. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243.
13. Humeau LM, et al. 2004. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol. Ther. 9:902-913.
14. Hutter G, et al. 2009. Long-term control of HIV by CCR5 Delta32/ Delta32 stem-cell transplantation. N. Engl. J. Med. 360:692-698.
15. Hutter G, Schneider T, Thiel E. 2009. Transplantation of selected or transgenic blood stem cells-a future treatment for HIV/AIDS? J. Int. AIDS Soc. 12:10.
16. Hutter G, Thiel E. 2011. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS 25:273-274.
17. Kambal A, et al. 2011. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Mol. Ther. 19:584-593.
18. Kohn DB, et al. 1999. A clinical trial of retroviral-mediated transfer of a Rev-responsive element decoy gene into CD34+cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94: 368-371.
19. Liu R, et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 86:267-377.
20. Martinez-Picado J, et al. 2000. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 97:10948-10953.
21. Michienzi A, Li S, Zaia JA, Rossi JJ. 2002. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc. Natl. Acad. Sci. U. S. A. 22:14047-14052.
22. Mitsuyasu RT, et al. 2009. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34++ cells. Nat. Med. 5:285-292.
23. Novina CD, et al. 2002. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8:681-686.
24. Nunez M. 2010. Clinical syndromes and consequences of antiretroviralrelated hepatotoxicity. Hepatology 52:1143-1155.
25. Sawyer SL, Emerman M, Malik HS. 2005. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. U. S. A. 102:2832-2837.
26. Seclen E, et al. 2010. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1 infected patients. J. Antimicrob. Chemother. 65:2502-2504.
27. Strayer DS, et al. 2005. Current status of gene therapy strategies to treat HIV/AIDS. Mol. Ther. 11:823-841.
28. Stremlau M, et al. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.
29. Veloso S, et al. 2010. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients. Curr. Pharm. Des. 16:3379-3389.